Neuphoria TherapeuticsNEUP -4.52%29 Net Current Asset Value is $3.03 as of Mar. 2026, which is 99% below its 10-year median of 460.20. GuruFocus rates NEUP with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Neuphoria Therapeutics ranks better than 89.71% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Neuphoria Therapeutics's net current asset value per share for the quarter that ended in Mar. 2026 was $3.03.
The historical rank and industry rank for Neuphoria Therapeutics's Net Current Asset Value or its related term are showing as below:
NEUP'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.86 Med: 460.2 Max: 7530
Current: 1.12
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Neuphoria Therapeutics was 7530.00. The lowest was 0.86. And the median was 460.20.
NEUP's Price-to-Net-Current-Asset-Value is ranked better than 89.71% of 943
companies
in the Biotechnology industry
Industry Median: 4.96
vs NEUP: 1.12
Neuphoria Therapeutics (NAS:NEUP) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Neuphoria Therapeutics Net Current Asset Value Related Terms
Neuphoria Therapeutics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Neuphoria Therapeutics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuphoria Therapeutics Net Current Asset Value Chart
NEUP vs PLRZ, SKYE, IGC: Net Current Asset Value Comparison
For the Biotechnology subindustry, Neuphoria Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuphoria Therapeutics Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Neuphoria Therapeutics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $3.03 mean?
Neuphoria Therapeutics (NEUP) has a Net Current Asset Value of $3.03 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Neuphoria Therapeutics and its competitors. This is 99% below median its historical median of 460.20. Over the past decade, Neuphoria Therapeutics' Net Current Asset Value has ranged from 0.86 to 7,530.00. According to the industry distribution chart, Neuphoria Therapeutics ranks #97 out of 943 companies in the Biotechnology industry, placing it in the top 10.3%.
Is Neuphoria Therapeutics' Net Current Asset Value too high?
Neuphoria Therapeutics' current Net Current Asset Value of $3.03 is 99% below median its 10-year median of 460.20. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 7,530.00. The Biotechnology industry median Net Current Asset Value is 4.96. Neuphoria Therapeutics' value of $3.03 is 38.9% below this industry median. Based on the distribution chart, Neuphoria Therapeutics ranks #97 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Net Current Asset Value compare to PLRZ and SKYE?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #97 out of 943 companies for Net Current Asset Value. This places Neuphoria Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.96. Neuphoria Therapeutics' value of $3.03 is 38.9% below this benchmark. Historically, Neuphoria Therapeutics' own Net Current Asset Value has ranged from 0.86 to 7,530.00 over the past decade. While the company's 10-year median is 460.20 vs. the industry median of 4.96, Neuphoria Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.96, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuphoria Therapeutics's current Net Current Asset Value of $3.03 is 38.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Neuphoria Therapeutics and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current Net Current Asset Value is $3.03, which is 99% below median its own 10-year median of 460.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Net Current Asset Value of $3.03. The current Net Current Asset Value is $3.03, which is 99% below median its 10-year median of 460.20 and 38.9% below the Biotechnology industry median of 4.96. Neuphoria Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Net Current Asset Value is $3.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
29GF Score
Get the complete analysis for NEUP
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEUP has been successfully added to your 
